Adjuvant compositions comprising a non-ionic isotonicity agent
AssigneeGlaxosmithkline Biologicals SA
InventorsVeronique Henderickx, Dominique Ingrid Lemoine
Life of this patent
Estimating the term…
Abstract
The present invention relates to an aqueous adjuvant composition comprising a TLR-4 agonist and a saponin in a liposomal formulation and a non-ionic isotonicity agent having low salt concentrations.
Claims26
-24. (canceled)
An aqueous adjuvant composition comprising:
- (a) a TLR-4 agonist and a saponin in a liposomal formulation;
- and (b) a non-ionic isotonicity agent, wherein the concentration of sodium chloride or the ionic strength in the adjuvant composition is less than 100 mM.
An aqueous adjuvant composition as claimed in claim 1 wherein the concentration of sodium chloride or ionic strength is less than 80 mM.
An aqueous adjuvant composition as claimed in claim 2 wherein the concentration of sodium chloride or ionic strength is less than 30 mM.
An aqueous adjuvant composition as claimed in claim 3 wherein the concentration of sodium chloride or ionic strength is less than 10 mM.
An aqueous adjuvant composition as claimed in claim 4 wherein the concentration of sodium chloride or ionic strength is less than 5 mM.
An aqueous adjuvant composition as claimed in claim 5 which contains essentially no sodium chloride.
An aqueous adjuvant composition according to claim 1 wherein the non-ionic isotonicity agent is a polyol.
An aqueous adjuvant composition according to claim 7 wherein the polyol is sorbitol.
The aqueous adjuvant composition of claim 8 wherein the concentration of sorbitol is between about 3% and about 15% (w/v).
An aqueous adjuvant composition of claim 9 wherein the concentration of sorbitol is between about 4% and about 10% (w/v).
The aqueous adjuvant composition of claim 1 wherein said TLR-4 agonist is 3D-MPL.
An aqueous adjuvant composition according to claim 1 wherein said saponin is QuilA or a derivative thereof.
An aqueous adjuvant composition according to claim 12 wherein the derivative of QuilA is QS21.
An aqueous adjuvant composition according to claim 1 comprising about 5 mM sodium chloride and between 5% and 6% w/v sorbitol.
An immunogenic composition comprising an antigen or antigenic preparation and the aqueous adjuvant composition of claim 1.
An immunogenic composition according to claim 15 wherein said antigen or antigenic preparation is not soluble in salt concentrations or in solutions wherein the ionic strength is higher than 100 mM.
An immunogenic composition of claim 16 wherein the antigen or antigenic preparation is derived from HIV, Neisseria meningitidis, or is a tumour associated antigen.
An immunogenic composition according to claim 17 wherein the antigen is selected from either PRAME or NY-ESO-1 or a fragment or derivative thereof.
An immunogenic composition according to claim 15 further comprising a CpG oligonucleotide.
A process for preparing an immunogenic composition comprising an antigen or antigenic preparation and the aqueous adjuvant composition of claim 1, the process comprising the step of reconstituting a lyophilised composition comprising the antigen or antigenic preparation with the aqueous adjuvant composition.
A kit comprising (i) a lyophilised composition comprising an antigen or antigenic preparation and (ii) an aqueous adjuvant composition according to claim 1.
The kit according to claim 21 wherein said lyophilised composition further comprises a TLR9 agonist.
The kit of claim 22 wherein said TLR9 agonist is a CpG immunostimulatory oligonucleotide.
The kit of claim 23 wherein the antigen or antigenic preparation is not soluble in salt concentrations or in solutions wherein the ionic strength is greater than 100 mM.
An immunogenic composition according to claim 15 wherein said antigen or antigenic preparation is not soluble in salt concentrations or in solutions wherein the ionic strength is higher than 5 mM.
Dependencies are inferred from the claim text.